NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, announced the closing of its business combination with Frazier Lifesciences Acquisition Corporation (Nasdaq:FLAC), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners. NewAmsterdam (Nasdaq:NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated.
Read the full article: NewAmsterdam Pharma Debuts as Publicly Traded Company //
Source: https://www.globenewswire.com/news-release/2022/11/23/2561557/0/en/NewAmsterdam-Pharma-Debuts-as-Publicly-Traded-Company-Focused-on-Developing-Obicetrapib-a-Low-Dose-Once-Daily-Oral-LDL-Lowering-Agent-with-Promising-Safety-and-Efficacy-Clinical-Da.html